Kimmo Porkka
Helsingin yliopisto
H-index: 70
Europe-Finland
Top articles of Kimmo Porkka
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Datamassojen hallinta syöpäpotilaiden hoidossa | Duodecim | Oskar Brück Kimmo Porkka | 2024 |
Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts | Blood Cancer Discovery | Elyse A Olesinski Karanpreet Singh Bhatia Chuqi Wang Marissa S Pioso Xiao Xian Lin | 2024/5/1 |
Integrated drug profiling and CRISPR screening identify BCR:: ABL1-independent vulnerabilities in chronic myeloid leukemia | Blood, The Journal of the American Society of Hematology | Olli Dufva Jan Koski Pilvi Maliniemi Aleksandr Ianevski Jay Klievink | 2020/2/27 |
Monosomy 7/del (7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia | Blood Advances | Samuli Eldfors Joseph Saad Nemo Ikonen Disha Malani Markus Vähä-Koskela | 2024/4/9 |
Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia | American Journal of Hematology | Keith W Pratz Brian A Jonas Vinod Pullarkat Michael J Thirman Jacqueline S Garcia | 2024/2/11 |
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐or very high‐risk myelodysplastic … | American journal of hematology | Andrew M Brunner Jordi Esteve Kimmo Porkka Steve Knapper Elie Traer | 2024/2 |
Real‐world experience of novel multiple myeloma treatments in a large, single‐center cohort in Finland | EJHaem | Heidi Loponen Juha Mehtälä Tero Ylisaukko‐oja Oscar Brück Kimmo Porkka | 2023/11 |
Early response evaluation by single cell signaling profiling in acute myeloid leukemia | Nature communications | Benedicte Sjo Tislevoll Monica Hellesøy Oda Helen Eck Fagerholt Stein-Erik Gullaksen Aashish Srivastava | 2023/1/7 |
Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia | Haematologica | Heikki Kuusanmäki Sari Kytölä Ida Vänttinen Tanja Ruokoranta Amanda Ranta | 2023/7/7 |
Identification of DHX40 as a candidate susceptibility gene for colorectal and hematological neoplasia | Leukemia | Alisa Olkinuora Taina T Nieminen Suvi Douglas Anni Kauppinen Mika Kontro | 2023/11 |
Targeting Mitochondrial Apoptotic Priming State to Personalize Therapy for Relapsed Acute Myeloid Leukemia | Blood | Elyse Olesinski Karanpreet Bhatia Chuqi Wang Marissa Pioso Shu Xuan Ng | 2023/11/28 |
Lääkeherkkyys ennakoi hoitovastetta leukemiassa | Duodecim | Heikki Kuusanmaki Sari Kytölä Ida Vänttinen Tanja Ruokoranta Amanda Ranta | 2023 |
Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial | Blood, The Journal of the American Society of Hematology | Lok Lam Ngai Diana Hanekamp Fleur Janssen Jannemieke Carbaat-Ham Maaike AMA Hofland | 2023/5/25 |
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively … | Haematologica | Jesse M Tettero Lok Lam Ngai Costa Bachas Dimitri A Breems Thomas Fischer | 2023/10/10 |
Primary Acute Myeloid Leukemia Cells Trigger Distinct Activation Patterns in Expanded NK Cells | Blood | Hanna Duàn Olli Dufva Emmi Jokinen Hanna Lähteenmäki Jay Klievink | 2023/11/28 |
Rekisteritietojen kerääminen harvinaisista sairauksista on erityisen tärkeää | Suomen lääkärilehti | Satu Wedenoja Kimmo Porkka Mikko Seppänen | 2023 |
Abstract CT026: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignancies | Cancer Research | Courtney D DiNardo Pau Montesinos Lina Benajiba Ana Triguero Christian Recher | 2023/4/14 |
Real-world evidence of multiple myeloma treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland | Future Oncology | Johanna Vikkula Kristiina Uusi-Rauva Tuuli Ranki Iiro Toppila Maria Aalto-Setälä | 2023/9 |
The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia | Blood | Lok Lam Ngai Diana Hanekamp Angèle Kelder Willemijn Scholten Jannemieke Carbaat-Ham | 2023/11/28 |
Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled … | American journal of hematology | Andrew H Wei Hartmut Döhner Hamid Sayar Farhad Ravandi Pau Montesinos | 2023/4 |
Co-Authors
